Integra LifeSciences Stock - Sunday background on risks and outlook

Integra LifeSciences stock trades quietly going into the new week, with investors weighing past quality issues, current valuation and earnings expectations. A Sunday background look highlights the business profile, key risks and what the calendar shows next for IART.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 20:03 CET. Details in the imprint.

Integra LifeSciences (US4579851036) is a US-based medical technology specialist whose stock reflects a mix of past setbacks and ongoing restructuring efforts. On this Sunday, the focus is on background, risk profile and outlook rather than a fresh headline event, based on recent analyst and data-provider summaries.

What recent data providers say

Data platforms describe Integra LifeSciences as a diversified supplier of surgical instruments and neurosurgical and wound-care products, targeting neurosurgery, neurocritical care and ear, nose and throat procedures. That mix places the company squarely in the mid-cap medtech universe.

Recent third-party analysis highlights valuation metrics, earnings estimates and a set of risk factors, rather than breaking corporate news. Earnings pages track the company’s quarterly results history and consensus expectations for upcoming reports.

Sunday background on risks and history

The current background debate around Integra LifeSciences still includes the reputational hit from historical quality-control issues in its tissue technologies segment, which previously led to recalls and remediation efforts according to earlier disclosures and news coverage. Investors continue to watch execution on remediation and margin recovery.

Analyst-style write-ups point to a combination of execution risk, regulatory scrutiny typical for medical device makers and competitive pressure in neurosurgery, orthopedics and wound care. At the same time, they underline the structural demand for procedures where Integra’s products are used.

How the earnings calendar looks

Quote and earnings pages show that Integra LifeSciences reports results on a typical quarterly cycle, with the latest closing price data available for mid-June 2026 and consensus earnings estimates updated around those dates. Detailed timing for the next call is usually confirmed on the IR site within weeks of the event.

According to one earnings tracker, Integra LifeSciences shares last closed around the high-teens in dollars in regular Nasdaq trading on 06/18/2026, with modest after-hours activity recorded the same evening. This keeps the market capitalization in the lower single-digit billion-dollar range.

The business behind the stock

Integra LifeSciences derives revenue from medical devices used in neurosurgery, instruments and orthopedic procedures, and advanced wound care. Its portfolio spans implants, monitoring tools and specialized surgical instruments for hospitals and clinics worldwide.

Where the stock trades today

Integra LifeSciences stock (US4579851036) trades on Nasdaq; based on the latest available quote for 06/18/2026 at 16:00 Eastern, the shares last changed hands at about $17.58, with extended-hours data showing a modest uptick later that evening.

Integra LifeSciences at a glance

• Company: Integra LifeSciences Holdings Corp.
• ISIN: US4579851036
• WKN: 886090
• Ticker: IART
• Venue: Nasdaq
• Price (as of 06/18/2026, 16:00 Eastern): 17.58 USD
• Market cap: roughly 1.4 billion USD (as of mid-June 2026)
• Sector / Industry: Health Care - Medical Devices
• Index membership: not a member of the Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.